Krunic A L, Garrod D R, Smith N P, Orchard G S, Cvijetic O B
Dermatologic Surgery Unit, Duke University Medical Center, Durham, North Carolina, USA.
Acta Derm Venereol. 1996 Sep;76(5):394-8. doi: 10.2340/0001555576394398.
The distinction between keratoacanthoma and squamous cell carcinoma is a common dermatopathological dilemma. Although the mainstay of the diagnosis is still clinico-pathological correlation, many dermatopathologists now include keratoacanthomas in the spectrum of squamous cell carcinomas. Recent reports, however, have pointed out that keratoacanthoma is "deficient squamous cell carcinoma" since it loses the expression of bcl-2 antigen, consistent with initiation of apoptosis, i.e. its involution. Electron microscope studies performed in keratoacanthomas and squamous cell carcinomas also revealed significantly reduced desmosomes in squamous cell carcinoma, but not in keratoacanthoma. A series of 38 keratoacanthomas and 62 squamous cell carcinomas of the skin (28 well-differentiated, 21 moderately differentiated and 13 poorly differentiated) were stained immunohistochemically with the monoclonal antibody 32-2B to desmosomal glycoproteins desmoglein 1 and desmoglein 3. Thirty-five keratoacanthomas showed extensive pericellular desmoglein expression. Three keratoacanthomas and 20 squamous cell carcinomas (19 well-differentiated, 1 moderately differentiated) showed focal staining, and in 11 squamous cell carcinomas (2 moderately differentiated, 9 poorly differentiated) the staining was negative. The remaining 31 squamous cell carcinomas (9 well differentiated, 18 moderately differentiated, 4 poorly differentiated) showed juxtanuclear staining. None of the squamous cell carcinomas exhibited the extensive pericellular pattern found in keratoacanthomas. Assessment of staining intensity, by 3 independent examiners, revealed a strong negative correlation between desmoglein expression and degree of dysplasia in the squamous cell carcinomas (p < 0.01). This antibody therefore clearly distinguishes these tumours and may be of value in the differential diagnosis of keratoacanthoma and squamous cell carcinomas in routine histopathology.
角化棘皮瘤与鳞状细胞癌的鉴别是常见的皮肤病理学难题。尽管诊断的主要依据仍是临床病理相关性,但现在许多皮肤病理学家将角化棘皮瘤纳入鳞状细胞癌范畴。然而,最近的报告指出,角化棘皮瘤是“缺陷性鳞状细胞癌”,因为它失去了bcl - 2抗原的表达,这与凋亡的启动即其 involution一致。对角化棘皮瘤和鳞状细胞癌进行的电子显微镜研究还显示,鳞状细胞癌中的桥粒明显减少,而角化棘皮瘤中则没有。用抗桥粒糖蛋白桥粒芯糖蛋白1和桥粒芯糖蛋白3的单克隆抗体32 - 2B对38例皮肤角化棘皮瘤和62例鳞状细胞癌(28例高分化、21例中分化和13例低分化)进行免疫组织化学染色。35例角化棘皮瘤显示广泛的细胞周围桥粒芯糖蛋白表达。3例角化棘皮瘤和20例鳞状细胞癌(19例高分化、1例中分化)显示局灶性染色,11例鳞状细胞癌(2例中分化、9例低分化)染色为阴性。其余31例鳞状细胞癌(9例高分化、18例中分化、4例低分化)显示核旁染色。没有一例鳞状细胞癌表现出角化棘皮瘤中发现的广泛细胞周围模式。由3名独立检查者评估染色强度,结果显示桥粒芯糖蛋白表达与鳞状细胞癌的发育异常程度之间存在强烈的负相关(p < 0.01)。因此,该抗体能清晰区分这些肿瘤,在常规组织病理学中对角化棘皮瘤和鳞状细胞癌的鉴别诊断可能具有价值。